Medical education article updated 10 November 2026. Prescribing should follow current local clinical guidelines and product information.
Overview
Asthma involves variable respiratory symptoms and variable expiratory airflow limitation. Treatment goals are symptom control and prevention of severe attacks, loss of lung function and medication harms. GINA 2026 emphasizes objective confirmation of the diagnosis, inhaler training and ICS-containing treatment rather than short-acting beta agonist (SABA) monotherapy [1,2].
Pharmacology of major classes
- Inhaled corticosteroids (ICS): budesonide, beclometasone, fluticasone and others engage intracellular glucocorticoid receptors to reduce inflammation.
- SABA: albuterol/salbutamol rapidly relaxes airway smooth muscle via β2–Gs–cAMP signaling but does not treat underlying inflammation.
- LABA: formoterol has rapid onset suitable for approved ICS-formoterol reliever strategies; salmeterol is not suitable as the reliever component of MART.
- Muscarinic antagonists: ipratropium may be added during severe exacerbation; tiotropium is a maintenance add-on for selected patients.
- Leukotriene receptor antagonist: montelukast blocks cysteinyl leukotriene type 1 receptors; it is less effective than ICS for preventing exacerbations in typical persistent asthma.
- Biologics: omalizumab (IgE), mepolizumab/reslizumab (IL-5), benralizumab (IL-5 receptor), dupilumab (IL-4 receptor α) and tezepelumab (TSLP) are phenotype-selected options for severe asthma [1,2].
GINA 2026 stepwise approach
For adults and adolescents, preferred Track 1 uses low-dose ICS-formoterol as the anti-inflammatory reliever, either as needed alone at earlier steps or as maintenance-and-reliever therapy (MART) for more frequent symptoms. Track 2 uses an ICS-SABA reliever or SABA reliever with appropriate ICS maintenance. SABA-only asthma care is not recommended. Do not use an ICS-formoterol reliever with a different non-formoterol maintenance LABA without an explicitly supported regimen. Children require age-specific recommendations [2].
Exacerbation treatment and follow-up
Acute attacks require immediate severity assessment, repeated inhaled SABA when indicated, oxygen titrated to appropriate targets, early systemic corticosteroids for moderate/severe attacks, and ipratropium for severe episodes. IV magnesium sulfate can be considered for selected severe attacks that respond poorly to initial therapy; propofol is not a routine bronchodilator. Before discharge, review an ICS-containing controller, inhaler technique, triggers and a written action plan [2].
Safety and precautions
ICS can cause dysphonia, oral candidiasis and at high cumulative exposure systemic adverse effects; rinse the mouth after maintenance ICS. β2 agonists can cause tremor, palpitations and hypokalemia at high doses. LABA monotherapy is unsafe in asthma. Montelukast carries a US boxed warning for serious neuropsychiatric events and is not preferred for routine mild allergic rhinitis when safer alternatives exist. Biologics have specific risks, eligibility requirements and monitoring [2,3].
Addressing difficult asthma
Before escalating to expensive biologics, verify diagnosis, adherence and technique; assess rhinosinusitis, obesity, smoking and other treatable traits, then phenotype using exacerbation history, blood eosinophils, IgE and other indicated markers. Avoid prolonged maintenance oral steroids where feasible [2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- Global Initiative for Asthma. GINA summary guide for asthma management and prevention. 2026. Available from: https://ginasthma.org/2026-gina-summary-guide/
- US Food and Drug Administration. Montelukast sodium prescribing information: boxed warning for neuropsychiatric events. 2026. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da038cf6-cfad-43a4-ab8e-d81d028d6087
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.